Small-molecule kinase inhibitors have made major advances in cancer therapy, but their efficacy remains limited by intrinsic and acquired resistance. The expression and thermostability of the kinase CDK6 are now shown to mediate intrinsic resistance to CDK4/6 inhibitors and degraders across cancer types.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Subbiah, V., Baik, C. & Kirkwood, J. M. Trends Cancer 6, 797–810 (2020).
Goel, S., DeCristo, M. J., McAllister, S. S. & Zhao, J. J. Trends Cell Biol. 28, 911–925 (2018).
Wu, X. et al. Nat. Cancer https://doi.org/10.1038/s43018-021-00174-z (2021).
Teh, J. L. F. & Aplin, A. E. Clin. Cancer Res. 25, 921–927 (2019).
AbuHammad, S. et al. Proc. Natl Acad. Sci. USA 116, 17990–18000 (2019).
Yang, C. et al. Oncogene 36, 2255–2264 (2017).
Verma, R., Mohl, D. & Deshaies, R. J. Mol. Cell 77, 446–460 (2020).
Su, S. et al. J. Med. Chem. 62, 7575–7582 (2019).
Brand, M. et al. Cell Chem. Biol. 26, 300–306.e9 (2019).
De Dominici, M. et al. Blood 135, 1560–1573 (2020).
Rana, S. et al. Bioorg. Med. Chem. Lett. 29, 1375–1379 (2019).
Khan, S. et al. Oncogene 39, 4909–4924 (2020).
Hallett, S. T. et al. Cell Rep. 21, 1386–1398 (2017).
Taipale, M. et al. Cell 150, 987–1001 (2012).
Teh, J. L. F. et al. Cancer Immunol. Res. 8, 1114–1121 (2020).
Acknowledgements
S.C. is supported by a Medical Student Research Award from the Melanoma Research Foundation. This work is supported by grants to A.E.A. from the National Cancer Institute of the US National Institutes of Health (R01 CA196278 and R01 CA160495).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.E.A. reports receiving a commercial research grant from Pfizer (2013-2017) and has ownership interest in patent number 9880150.
Rights and permissions
About this article
Cite this article
Caksa, S., Aplin, A.E. PROactively TACkling CDK4/6 therapy resistance. Nat Cancer 2, 372–373 (2021). https://doi.org/10.1038/s43018-021-00193-w
Published:
Issue date:
DOI: https://doi.org/10.1038/s43018-021-00193-w
